AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17562667 — intervention group
Group type: COMPARATOR
Intervention: Control group (exercise training adhering to current guidelines)
Number of subjects: 22
Study 17562667 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemic group
Number of subjects: 22
Study 16095462 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine 10 mg/h + morphine 0.16 mg/h (Group L)
Number of subjects: 45
Study 16095462 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine 16 mg/h + morphine 0.16 mg/h (Group H)
Number of subjects: 45
Study 16095462 — intervention group
Group type: COMPARATOR
Intervention: Placebo PCA morphine (Group PL)
Number of subjects: 45
Study 11861242 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol
Number of subjects: 19
Study 11861242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 10459904 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate surgery (ventilation-tube insertion) within 6 weeks (n=92)
Number of subjects: 186
Study 10459904 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting for 9 months (n=90)
Number of subjects: 186
Study 10459904 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups after 18 months
Number of subjects: 186
Study 7791061 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 1% apraclonidine, one drop before and after surgery
Number of subjects: 54
Study 7791061 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release acetazolamide, 500 mg
Number of subjects: 54
Study 7791061 — intervention group
Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 54
Study 2152944 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro best regimen (IVBR), a three-drug combination of proved efficacy in SCLC, administered as secondary therapy to patients with partial or no responses after primary therapy.
Number of subjects: 80
Study 2152944 — intervention group
Group type: COMPARATOR
Intervention: Empiric combination of vincristine-doxorubicin-cyclophosphamide, administered as secondary therapy when DST data were unavailable.
Number of subjects: 80
Study 2152944 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary therapy with etoposide and cisplatin, followed by restaging after 12 weeks.
Number of subjects: 80
Study 2152944 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro drug sensitivity testing (DST) data used to select chemotherapy.
Number of subjects: 80
Study 2152944 — intervention group
Group type: EXPERIMENTAL
Intervention: IVBR as secondary therapy.
Number of subjects: 80
Study 359121 — intervention group
Group type: EXPERIMENTAL
Intervention: 5FU infusion with Mitomycin-C
Number of subjects: 0
Study 359121 — intervention group
Group type: COMPARATOR
Intervention: 5FU infusion with Methyl-CCNU
Number of subjects: 0
Study 31078338 — intervention group
Group type: EXPERIMENTAL
Intervention: BPI surgery patients
Number of subjects: 1936
Study 31078338 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-naive BPI patients
Number of subjects: 1936
Study 31078338 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-BPI patients)
Number of subjects: 1936
Study 29408760 — intervention group
Group type: EXPERIMENTAL
Intervention: Zataria multiflora 5 mg/kg/day
Number of subjects: 47
Study 29408760 — intervention group
Group type: EXPERIMENTAL
Intervention: Zataria multiflora 10 mg/kg/day
Number of subjects: 47
Study 29408760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 27578482 — intervention group
Group type: EXPERIMENTAL
Intervention: HFNC (High Flow Nasal Cannula)
Number of subjects: 0
Study 25348614 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention consisting of transplant education and engagement activities targeting dialysis facility leadership, staff, and patients.
Number of subjects: 134
Study 25348614 — intervention group
Group type: COMPARATOR
Intervention: Standard of care or 'usual' transplant education.
Number of subjects: 134
Study 22354664 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO2) at 3 ATA for 10 consecutive days
Number of subjects: 1
Study 22354664 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO2)
Number of subjects: 1
Study 22354664 — intervention group
Group type: COMPARATOR
Intervention: High pressure (up to 3 ATA) alone
Number of subjects: 1
Study 22354664 — intervention group
Group type: COMPARATOR
Intervention: Pure oxygen alone
Number of subjects: 1
Study 19818077 — intervention group
Group type: COMPARATOR
Intervention: Solifenacin 5 mg once daily (od) alone
Number of subjects: 643
Study 19818077 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg od combined with simplified bladder training
Number of subjects: 643
Study 19818077 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg od (after dose increase)
Number of subjects: 643
Study 17605004 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg
Number of subjects: 10
Study 17605004 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg
Number of subjects: 10
Study 17605004 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 200 mg
Number of subjects: 10
Study 17605004 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 400 mg
Number of subjects: 10
Study 17605004 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 0.1 mg IM
Number of subjects: 10
Study 17605004 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 0.2 mg IM
Number of subjects: 10
Study 17605004 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 15 mg IM
Number of subjects: 10
Study 17605004 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 30 mg IM
Number of subjects: 10
Study 17605004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 17056608 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced pharmacy review
Number of subjects: 325
Study 17056608 — intervention group
Group type: EXPERIMENTAL
Intervention: Community physiotherapy
Number of subjects: 325
Study 17056608 — intervention group
Group type: COMPARATOR
Intervention: Control (advice leaflet reinforced by telephone call)
Number of subjects: 325
Study 12064335 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced changes in coffee consumption
Number of subjects: 214
Study 10359389 — intervention group
Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 4075
Study 10359389 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 4075
Study 10359389 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonylurea
Number of subjects: 4075
Study 10359389 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (in obese patients)
Number of subjects: 4075
Study 8530606 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandostatin LAR 20 mg
Number of subjects: 29
Study 8530606 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandostatin LAR 30 mg
Number of subjects: 29
Study 8530606 — intervention group
Group type: COMPARATOR
Intervention: Sandostatin LAR (3, 6, 9, or 12 mg)
Number of subjects: 29
Study 8530606 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandostatin LAR
Number of subjects: 29
Study 1779103 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel‐Larmes
Number of subjects: 0
Study 1779103 — intervention group
Group type: COMPARATOR
Intervention: Chondroitin sulphate eye drops
Number of subjects: 0
Study 6123069 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Dihydergot (0.25 mg i.v.) and etilefrine (15 mg p.o.)
Number of subjects: 29
Study 6123069 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Dihydergot (2 mg) and etilefrine (20 mg)
Number of subjects: 29
Study 6123069 — intervention group
Group type: EXPERIMENTAL
Intervention: Etilefrine (20 mg)
Number of subjects: 29
Study 6123069 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydergot (2 mg)
Number of subjects: 29
Study 6123069 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.25 Dihydergot i.v.)
Number of subjects: 29
Study 31369841 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo mouthwash
Number of subjects: 23
Study 31369841 — intervention group
Group type: COMPARATOR
Intervention: Antibacterial mouthwash
Number of subjects: 23
Study 28826740 — intervention group
Group type: EXPERIMENTAL
Intervention: Parnaparin sodium (low-molecular weight heparin) for the whole cycle
Number of subjects: 247
Study 28826740 — intervention group
Group type: COMPARATOR
Intervention: Routine hormonal therapy only
Number of subjects: 247
Study 25573831 — intervention group
Group type: EXPERIMENTAL
Intervention: MRA-naïve patients
Number of subjects: 842
Study 25573831 — intervention group
Group type: EXPERIMENTAL
Intervention: MRA-treated patients
Number of subjects: 842
Study 25573831 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup with low cortisol and high aldosterone
Number of subjects: 842
Study 25573831 — intervention group
Group type: COMPARATOR
Intervention: Total cohort
Number of subjects: 842
Study 24075374 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI) combined with ovarian stimulation
Number of subjects: 703
Study 24075374 — intervention group
Group type: COMPARATOR
Intervention: Control group (unexplained infertility)
Number of subjects: 703
Study 21419287 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal infiltration of 4% articaine with 1:100,000 epinephrine
Number of subjects: 94
Study 21419287 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal infiltration of 1 mL/30 mg of ketorolac tromethamine (after 0.9 mL of 4% articaine)
Number of subjects: 94
Study 21419287 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental buccal infiltration of 1 mL/4 mg of dexamethasone
Number of subjects: 94
Study 21419287 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplemental infiltration)
Number of subjects: 94
Study 19548436 — intervention group
Group type: EXPERIMENTAL
Intervention: Qihong Decoction (QHD) combined with routine treatment
Number of subjects: 72
Study 19548436 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment alone
Number of subjects: 72
Study 16787719 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/day) for 6 months
Number of subjects: 40
Study 16787719 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 40
Study 14747233 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone 4 mg b.i.d. for 12 weeks
Number of subjects: 12
Study 14747233 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Number of subjects: 12
Study 14747233 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone with co-infusion of exogenous insulin
Number of subjects: 12
Study 14747233 — intervention group
Group type: COMPARATOR
Intervention: nateglinide 60 mg b.i.d. for 12 weeks
Number of subjects: 12
Study 10381039 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic strength training (EG) 2 times a week with moderate loads of 50-70% of repetition maximum.
Number of subjects: 65
Study 10381039 — intervention group
Group type: COMPARATOR
Intervention: Recreational physical activities and range of motion exercises (CG).
Number of subjects: 65
Study 10381039 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic strength training (EG).
Number of subjects: 65
Study 8674257 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 13
Study 8674257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 1908192 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of epidural diamorphine at a rate of 1 mg/hour (group 1)
Number of subjects: 22
Study 1908192 — intervention group
Group type: COMPARATOR
Intervention: Bolus doses of epidural diamorphine 5 mg on demand (group 2)
Number of subjects: 22
Study 1908192 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study 6345330 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAAs (40 gm per day) in 5% glucose
Number of subjects: 50
Study 6345330 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5% glucose)
Number of subjects: 50
Study 29998740 — intervention group
Group type: EXPERIMENTAL
Intervention: Remaking Recess with implementation support
Number of subjects: 31
Study 29998740 — intervention group
Group type: COMPARATOR
Intervention: Remaking Recess (without implementation support)
Number of subjects: 31
Study 29998740 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Remaking Recess and Remaking Recess with implementation support)
Number of subjects: 31
Study 28958424 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow work pace
Number of subjects: 18
Study 28958424 — intervention group
Group type: COMPARATOR
Intervention: Fast work pace
Number of subjects: 18
Study 28958424 — intervention group
Group type: EXPERIMENTAL
Intervention: Active pauses
Number of subjects: 18
Study 28958424 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive pauses
Number of subjects: 18
Study 25619917 — intervention group
Group type: EXPERIMENTAL
Intervention: Highlighted prompts
Number of subjects: 4
Study 25619917 — intervention group
Group type: COMPARATOR
Intervention: Not highlighted prompts
Number of subjects: 4
Study 25619917 — intervention group
Group type: EXPERIMENTAL
Intervention: High-priority highlighted prompts
Number of subjects: 4
Study 25619917 — intervention group
Group type: COMPARATOR
Intervention: High-priority prompts from the previous year (not highlighted)
Number of subjects: 4
Study 22549655 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual needle placement (n=42)
Number of subjects: 81
Study 22549655 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation guidance (n=39)
Number of subjects: 81
Study 22549655 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrocnemius medialis
Number of subjects: 81
Study 22549655 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrocnemius lateralis
Number of subjects: 81
Study 20046181 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunochromatographic test (ICT) for antigen
Number of subjects: 98
Study 20046181 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunochromatographic test (ICT) for antibody
Number of subjects: 98
Study 20046181 — intervention group
Group type: COMPARATOR
Intervention: Microscopic examination of peripheral blood film
Number of subjects: 98
Study 19040391 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayurvedic formulation 'varuna and banana stem' (active treatment)
Number of subjects: 77
Study 19040391 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 77
Study 16077391 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump surgery
Number of subjects: 35
Study 16077391 — intervention group
Group type: COMPARATOR
Intervention: Off-pump surgery
Number of subjects: 35
Study 16077391 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 35
Study 12459689 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 12
Study 12459689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10509459 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct palpation
Number of subjects: 20
Study 10509459 — intervention group
Group type: COMPARATOR
Intervention: Conventional instruments
Number of subjects: 20
Study 10509459 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic instruments
Number of subjects: 20
Study 8934383 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 1755059 — intervention group
Group type: EXPERIMENTAL
Intervention: ivermectin
Number of subjects: 1745
Study 1755059 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1745
Study 6580659 — intervention group
Group type: EXPERIMENTAL
Intervention: Piridoxilate
Number of subjects: 40
Study 6580659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30080432 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 16
Study 30080432 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 16
Study 30043092 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 70 micro g/day (2800 IU/day)
Number of subjects: 81
Study 30043092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 26836465 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive aid available (7 of 13 groups)
Number of subjects: 13
Study 26836465 — intervention group
Group type: COMPARATOR
Intervention: No cognitive aid available (6 of 13 groups)
Number of subjects: 13
Study 26836465 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (13 groups)
Number of subjects: 13
Study 24563518 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual inspection with acetic acid (VIA) screening by primary health workers
Number of subjects: 151538
Study 24563518 — intervention group
Group type: COMPARATOR
Intervention: Control group (cancer education offered once)
Number of subjects: 151538
Study 22215183 — intervention group
Group type: EXPERIMENTAL
Intervention: 50,000 IU vitamin D3 monthly
Number of subjects: 110
Study 22215183 — intervention group
Group type: EXPERIMENTAL
Intervention: 50,000 IU vitamin D3 alternate months
Number of subjects: 110
Study 22215183 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 50,000 IU dose pre-departure
Number of subjects: 110
Study 22215183 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 110
Study 22215183 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 110
Study 20177280 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive vaginal ring
Number of subjects: 273
Study 20177280 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptive pill (OCP)
Number of subjects: 273
Study 17394627 — intervention group
Group type: EXPERIMENTAL
Intervention: Biatain-Ibu non adhesive foam dressing with ibuprofen
Number of subjects: 122
Study 17394627 — intervention group
Group type: COMPARATOR
Intervention: Biatain non adhesive foam without ibuprofen
Number of subjects: 122
Study 17975958 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-power laser irradiation (780 nm; power, 250 mW)
Number of subjects: 18
Study 17975958 — intervention group
Group type: COMPARATOR
Intervention: Placebo (non-active light: diffused LED lamp)
Number of subjects: 18
Study 15487437 — intervention group
Group type: EXPERIMENTAL
Intervention: Syllogisms with a causal conditional premise that can be extended by an agency premise
Number of subjects: 0
Study 15487437 — intervention group
Group type: COMPARATOR
Intervention: Control content syllogisms
Number of subjects: 0
Study 10671963 — intervention group
Group type: EXPERIMENTAL
Intervention: Nels cream (containing chloroxylenol and zinc oxide)
Number of subjects: 41
Study 10671963 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% benzoyl peroxide cream
Number of subjects: 41
Study 10671963 — intervention group
Group type: COMPARATOR
Intervention: Vehicle of the Nels cream
Number of subjects: 41
Study 9091691 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief physician advice (two 10- to 15-minute counseling visits using a scripted workbook)
Number of subjects: 723
Study 9091691 — intervention group
Group type: COMPARATOR
Intervention: Control group (no brief physician advice)
Number of subjects: 723
Study 1552408 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of nebulized cromolyn sodium
Number of subjects: 0
Study 1552408 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 0
Study 4053214 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenampicillin (LAPC) - single dose (250 mg)
Number of subjects: 6
Study 4053214 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin (AMPC) - single dose (500 mg)
Number of subjects: 6
Study 4053214 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenampicillin (LAPC) - multiple dose (250 mg twice a day for 8 days)
Number of subjects: 6
Study 4053214 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin (AMPC) - multiple dose (500 mg twice a day for 8 days)
Number of subjects: 6
Study 4053214 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenampicillin (LAPC)
Number of subjects: 6
Study 4053214 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin (AMPC)
Number of subjects: 6
Study 31441936 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant financial incentive ($0.00020 per step)
Number of subjects: 3515
Study 31441936 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreasing financial incentive ($0.00020 per step)
Number of subjects: 3515
Study 31441936 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing financial incentive ($0.00020 per step)
Number of subjects: 3515
Study 31441936 — intervention group
Group type: COMPARATOR
Intervention: Control group ($0.00001 per step)
Number of subjects: 3515
Study 29466159 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg daily)
Number of subjects: 3424
Study 29466159 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban (10 mg daily for 5 days, then continued or switched to aspirin)
Number of subjects: 3424
Study 25524327 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 µg/day selenium
Number of subjects: 230
Study 25524327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study 24381263 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor beta synchrony (MBS) reduction
Number of subjects: 0
Study 24381263 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher incentives
Number of subjects: 0
Study 24381263 — intervention group
Group type: EXPERIMENTAL
Intervention: MBS reduction at the beginning of rest periods
Number of subjects: 0
Study 24381263 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive effects on MBS reduction and rest duration
Number of subjects: 0
Study 24381263 — intervention group
Group type: EXPERIMENTAL
Intervention: MBS reduction
Number of subjects: 0
Study 21617159 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care panel assessment of CK-MB(mass), myoglobin, and troponin
Number of subjects: 2243
Study 21617159 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 2243
Study 20068435 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonography-guided injection of botulinum toxin A into calf muscles
Number of subjects: 32
Study 20068435 — intervention group
Group type: COMPARATOR
Intervention: Electric stimulation-guided injection of botulinum toxin A into calf muscles
Number of subjects: 32
Study 17105841 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin + OCP
Number of subjects: 48